🇺🇸 FDA

Company profile · Sponsor

Instituto

Instituto Grifols S.A.

ECF2E68 · EMA pharma EU
Pipeline
2
Drugs
0
Patents
0

Quick answer

Instituto (ECF2E68) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 2 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker ECF2E68
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (2)

Search pipeline →

  1. Albutein 50 g/l solución para perfusión.

    Instituto

    Subjects with cirrhosis with ACLF-1b, ACLF-2, or ACLF-3a detected either at admission or during hospitalization

    phase 3 small molecule active

    1 trial

  2. Prolastin 1000 mg, Pulver und Lösungsmittel zur Her- stellung einer Infusionslösung, Prolastin 5000 mg, Pulver und Lösungsmittel zur Herstellung einer Infusionslösung, Prolastin 4000 mg, Pulver und Lösungsmittel zur Herstellung einer Infusionslösung

    Instituto

    Severe Alpha-1 Antitrypsin Deficiency (AATD)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is Instituto?

Instituto (ECF2E68) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 2 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Instituto sponsor?

We track 2 ClinicalTrials.gov-linked programs for Instituto, including Albutein 50 g/l solución para perfusión. and 1 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Instituto company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.